Equillium (NASDAQ:EQ) COO Sells $150,000.00 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 100,000 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00. Following the transaction, the chief operating officer directly owned 91,444 shares in the company, valued at approximately $137,166. This represents a 52.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The shares were sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The stock was sold at an average price of $1.34, for a total transaction of $31,897.36.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The stock was sold at an average price of $0.95, for a total value of $7,693.10.

Equillium Stock Performance

Equillium stock traded down $0.05 during mid-day trading on Tuesday, reaching $1.35. The stock had a trading volume of 1,939,959 shares, compared to its average volume of 2,594,987. The firm has a market capitalization of $82.20 million, a PE ratio of -2.18 and a beta of 1.93. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $2.35. The stock’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.02.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.08. On average, research analysts forecast that Equillium, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Equillium

A number of institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC purchased a new stake in shares of Equillium during the third quarter worth $7,951,000. Woodline Partners LP purchased a new position in Equillium during the 3rd quarter valued at about $5,018,000. Vanguard Group Inc. grew its holdings in Equillium by 59.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after buying an additional 489,855 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Equillium during the third quarter valued at about $608,000. Finally, Aberdeen Group plc purchased a new stake in shares of Equillium in the third quarter worth about $543,000. 27.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EQ has been the subject of several recent research reports. Wall Street Zen upgraded Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a research report on Monday. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Equillium currently has an average rating of “Reduce” and a consensus target price of $1.00.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.